Caring Ambassadors Program

Hepatitis C Newsletter

www.HepCChallenge.org

September 2011

Clinical Trials, Cohort Studies, Pilot Studies

Multiple ascending dose study of BMS-790052, an NS5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1.

Nettles RE, Gao M, Bifano M, et al. Hepatology. 2011 Aug 11. doi: 10.1002/hep.24609. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21837752

Efficacy of pegylated interferon plus ribavirin combination therapy for hepatitis C patients with normal ALT levels: a matched case-control study. Hiramatsu N, Inoue Y, Oze T, et al. J Gastroenterol. 2011 Aug 20. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21858637

Pegylated interferon-Alfa-2a monotherapy in patients infected with HCV genotype 2 and importance of rapid virological response. Etoh R, Imazeki F, Kurihara T, et al. BMC Res Notes. 2011 Aug 31;4(1):316. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21884572

Development rate of chronic kidney disease in hepatitis C virus patients with advanced fibrosis after interferon therapy. Arase Y, Suzuki F, Kawamura Y, et al. Hepatol Res. 2011 Aug 24. doi: 10.1111/j.1872-034X.2011.00845.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21883737

Antiviral Activity of Danoprevir (ITMN-191/RG7227) in Combination With Pegylated Interferon {alpha}-2a and Ribavirin in Patients With Hepatitis C. Forestier N, Larrey D, Marcellin P, Guyader D, et al. J Infect Dis. 2011 Aug;204(4):601-8.

http://www.ncbi.nlm.nih.gov/pubmed/21791662

Retreatment of patients with chronic hepatitis C relapsers to a previous antiviral treat-ment. Floreani A, Cazzagon N, Furlan P, et al. Eur J Gastroenterol Hepatol. 2011 Aug;23(8):711-5.

http://www.ncbi.nlm.nih.gov/pubmed/21654322

Effects of mutation number in interferon sensitivity determining region on peripheral blood CD4(+) T cell subsets (Th1, Th2) in chronic hepatitis C patients with hepatitis C virus genotype 1b and high viral load. Ishii K, Shinohara M, Kogame M, et al. Hepatol Int. 2011 Aug 6. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21818686

Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males. White DL, Tavakoli-Tabasi S, Kuzniarek J, Pascua R, Ramsey DJ, El-Serag HB. Hepatology. 2011 Aug 19. doi: 10.1002/hep.24618. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21858849

Changes in Depressive Symptoms and Impact on Treatment Course Among Hepatitis C Patients Undergoing Interferon-α and Ribavirin Therapy: A Prospective Evaluation.

Chapman J, Oser M, Hockemeyer J, Weitlauf J, Jones S, Cheung R. Am J Gastroenterol. 2011 Aug 9. doi: 10.1038/ajg.2011.252. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21826113

Basic and Applied Science, Pre-Clinical Studies

Selection of hepatitis C virus resistant to ribavirin. Feigelstock DA, Mihalik KB, Feinstone SM. Virol J. 2011 Aug 15;8(1):402. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21843317

Effects of hypolipidemic agent nordihydroguaiaretic acid on lipid droplets and hepatitis C virus. Syed GH, Siddiqui A. Hepatology. 2011 Aug 19. doi: 10.1002/hep.24619. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21858850

The effect of cytokine profiles on the viral response to re-treatment in antiviral-experienced patients with chronic hepatitis C virus infection. Zhang Y, Guo D, Zhao Y, et al. Antiviral Res. 2011 Aug 26. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21889543

The Hepatitis C Virus E1 Glycoprotein Undergoes Productive Folding but Accelerated Degradation When Expressed as an Individual Subunit in CHO Cells. Botti V, Bianchi A, Foung SK, Merola M. PLoS One. 2011;6(8):e23838. Epub 2011 Aug 17.

http://www.ncbi.nlm.nih.gov/pubmed/21858229

Mutations in the E2 and NS5A regions in patients infected with hepatitis C virus genotype 1a and their correlation with response to treatment. Yahoo N, Sabahi F, Shahzamani K, et al. J Med Virol. 2011 Aug;83(8):1332-7. doi: 10.1002/jmv.22144.

http://www.ncbi.nlm.nih.gov/pubmed/21678437

Mitochondrial-associated endoplasmic reticulum membranes (MAM) form innate immune synapses and are targeted by hepatitis C virus. Horner SM, Liu HM, Park HS, Briley J, Gale M Jr. Proc Natl Acad Sci U S A. 2011 Aug 15. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21844353

A polymorphism that delays fibrosis in hepatitis C promotes alternative splicing of AZIN1, reducing fibrogenesis. Paris AJ, Snapir Z, Christopherson CD, et al. Hepatology. 2011 Aug 11. doi: 10.1002/hep.24608. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21837750

Zebrafish as a potential model organism for drug test against hepatitis C virus. Ding CB, Zhang JP, Zhao Y, Peng ZG, Song DQ, Jiang JD. PLoS One. 2011;6(8):e22921. Epub 2011 Aug 8.

http://www.ncbi.nlm.nih.gov/pubmed/21857967

Ceestatin, a novel small molecule inhibitor of hepatitis C virus replication, inhibits 3-hydroxy-3-methylglutaryl-coenzyme a synthase. Peng LF, Schaefer EA, Maloof N, et al. J Infect Dis. 2011 Aug;204(4):609-16.

http://www.ncbi.nlm.nih.gov/pubmed/21791663

HIV/HCV Coinfection

Patient and Provider Characteristics Associated with the Decision of HIV Coinfected Patients to Start Hepatitis C Treatment. Osilla KC, Wagner G, Garnett J, Ghosh-Dastidar B, Witt M, Bhatti L, Goetz MB. AIDS Patient Care STDS. 2011 Sep;25(9):533-8. Epub 2011 Aug

http://www.ncbi.nlm.nih.gov/pubmed/21823907

Association of Vpu with hepatitis C virus NS3/4A stimulates transcription of type 1 human immunodeficiency virus. Kang L, Luo Z, Li Y, et al. Virus Res. 2011 Aug 25. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21889553

A Higher Correlation of HCV Core Antigen with CD4+ T Cell Counts Compared with HCV RNA in HCV/HIV-1 Coinfected Patients. Shen T, Chen X, Zhang W, et al. PLoS One. 2011;6(8):e23550. Epub 2011 Aug 12.

http://www.ncbi.nlm.nih.gov/pubmed/21858166

Treatment of chronic hepatitis C in HIV-infected patients with compensated liver cirrhosis.

Martín-Carbonero L, Tuma P, Vispo E, et al. J Viral Hepat. 2011 Aug;18(8):542-8. doi: 10.1111/j.1365-2893.2010.01334.x. Epub 2010 Aug 31.

http://www.ncbi.nlm.nih.gov/pubmed/20819149

Positive impact of HCV treatment on ART adherence in HIV-HCV coinfected patients: one more argument for expanded access to HCV treatment for IDUs. Roux P, Fugon L, Winnock M, et al. Addiction. 2011 Aug 5. doi: 10.1111/j.1360-0443.2011.03608.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21819472

Challenges Facing Providers Caring for HIV/HCV-Coinfected Patients. Lekas HM, Siegel K, Leider J. Qual Health Res. 2011 Aug 8. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21825278

Reliability and predictive validity of a hepatitis-related symptom inventory in HIV-infected individuals referred for Hepatitis C treatment. Cachay ER, Wyles DL, Goicoechea M, et al. AIDS Res Ther. 2011 Aug 10;8(1):29. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21831314

The Impact of Hepatitis C Coinfection on Kidney Disease Related to Human Immuno-deficiency Virus (HIV): A Biopsy Study. George E, Nadkarni GN, Estrella MM, Lucas GM, Sperati CJ, Atta MG, Fine DM. Medicine (Baltimore). 2011 Aug 18. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21857365

Assessment of liver disease (noninvasive methods). Mehta SH, Buckle GC. Curr Opin HIV AIDS. 2011 Aug 18. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21857222

European mitochondrial DNA haplogroups and liver fibrosis in HIV and hepatitis C virus coinfected patients. García-Álvarez M, Guzmán-Fulgencio M, Berenguer J, et al. AIDS. 2011 Aug 24;25(13):1619-1926.

http://www.ncbi.nlm.nih.gov/pubmed/21673559

Acute Hepatitis C Virus in an HIV Clinic: A Screening Strategy, Risk Factors, and Perception of Risk. Taylor LE, Delong AK, Maynard MA, et al. AIDS Patient Care STDS. 2011 Aug 22. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21859307

Gender Differences in liver Fibrosis and Hepatitis C Virus-related Parameters in Patients Coinfected with Human Immunodeficiency Virus. Collazos J, Cartón JA, Asensi V. Curr HIV Res. 2011 Aug 9. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21827383

Randomized Trial Comparing Dose Reduction and Growth Factor Supplementation for Management of Hematological Side Effects in HIV/HCV Patients Receiving Pegylated-Interferon and Ribavirin. Talal AH, Liu RC, Zeremski M, et al. J Acquir Immune Defic Syndr. 2011 Aug 26. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21876446

management strategies for anemia and neutropenia in HIV/HCV co-infected individuals treated with PEG-IFN/RBV.

Complementary and Alternative Medicine

The green tea polyphenol epigallocatechin-3-gallate (EGCG) inhibits hepatitis C virus (HCV) entry. Ciesek S, von Hahn T, Colpitts CC, et a;/ Hepatology. 2011 Aug 11. doi: 10.1002/hep.24610. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21837753

Epidemiology, Diagnostics, and Miscellaneous Works

Risk Factors for Liver Disease and Associated Knowledge and Practices Among Mexican Adults in the US and Mexico. Flores YN, Lang CM, Salmerón J, Bastani R. J Community Health. 2011 Aug 30. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21877109

Temporal changes in HCV genotype distribution in three different high risk populations in San Francisco, California. Telles Dias P, Hahn JA, Delwart E, et al. BMC Infect Dis. 2011 Aug 2;11(1):208. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21810243

Usefulness of a novel serum proteome-derived index FI-PRO (fibrosis-protein) in the prediction of fibrosis in chronic hepatitis C. Cheung KJ, Tilleman K, Deforce D, et al. Eur J Gastroenterol Hepatol. 2011 Aug;23(8):701-10.

http://www.ncbi.nlm.nih.gov/pubmed/21623191

IL28B polymorphism and genetic biomarkers of viral clearance in hepatitis C virus infection. Holmes JA, Sievert W, Thompson AJ. Biomark Med. 2011 Aug;5(4):461-78.

http://www.ncbi.nlm.nih.gov/pubmed/21861668

Peripheral blood monocyte subsets predict antiviral response in chronic hepatitis C.

Rodríguez-Muñoz Y, Martín-Vílchez S, López-Rodríguez R, et al. Aliment Pharmacol Ther. 2011 Aug 17. doi: 10.1111/j.1365-2036.2011.04807.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21848603

Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Smith KR, Suppiah V, O'Connor K, et al. Genome Med. 2011 Aug 31;3(8):57. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21884576

FibroTest(®) and Fibroscan(®) performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate. Poynard T, de Ledinghen V, Zarski JP, et al. Clin Res Hepatol Gastroenterol. 2011 Aug 16. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21852224

Relative performances of FibroTest, Fibroscan and biopsy for assessing the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard. Poynard T, de Ledinghen V, Zarski JP, et al. J Hepatol. 2011 Aug 31. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21889468

Hepatorenal Syndrome: Are We Missing Some Prognostic Factors? Martinez MO, Sayles H, Vivekanandan R, D' Souza S, Florescu MC. Dig Dis Sci. 2011 Aug 18. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21850494

Dermatological side effects of hepatitis c and its treatment: Patient management in the era of direct-acting antivirals. Cacoub P, Bourlière M, Lübbe J, et al. J Hepatol. 2011 Aug 29. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21884670

Economic Burden Associated With Patients Diagnosed With Hepatitis C. McCombs JS, Yuan Y, Shin J, Saab S. Clin Ther. 2011 Aug 11. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21840056

Liver Cancer

Integrative network analysis identifies key genes and pathways in the progression of hepatitis C virus induced hepatocellular carcinoma.

Zheng S, Tansey WP, Hiebert SW, Zhao Z. BMC Med Genomics. 2011 Aug 8;4(1):62. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21824427

Level of Alpha-Fetoprotein Predicts Mortality among Patients with Hepatitis C-Related Hepatocellular Carcinoma. Tyson GL, Duan Z, Kramer JR, Davila JA, Richardson PA, El-Serag HB. Clin Gastroenterol Hepatol. 2011 Aug 3. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21820396

Occurrence of Hepatocellular Carcinoma Was Not a Rare Event during and Immediately after Antiviral Treatment in Japanese HCV-Positive Patients. Kanda T, Imazeki F, Mikami S, et al. Oncology. 2011 Aug 3;80(5-6):366-372. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21822027

Amino Acid substitutions in the hepatitis C virus core region are associated with post-operative recurrence and survival of patients with HCV genotype 1b-associated hepatocellular carcinoma. Toyoda H, Kumada T, Kaneoka Y, Maeda A. Ann Surg. 2011 Aug;254(2):326-32.

http://www.ncbi.nlm.nih.gov/pubmed/21709542

Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Lok AS, Everhart JE, Di Bisceglie AM, et al. Hepatology. 2011 Aug;54(2):434-42. doi: 10.1002/hep.24257.

http://www.ncbi.nlm.nih.gov/pubmed/21374690

Building a comprehensive genomic program for hepatocellular carcinoma. Harring TR, Guiteau JJ, Nguyen NT, et al. World J Surg. 2011 Aug;35(8):1746-50.

http://www.ncbi.nlm.nih.gov/pubmed/21225260